Group 1 - The article reports administrative penalties imposed by the Shaanxi Financial Regulatory Bureau on China People's Property Insurance Company, Shanzhou Branch, and Xi'an Branch for regulatory violations [1][2] - The Shanzhou Branch was fined 5,000 RMB for failing to register and obtain a business license as required by market supervision authorities [1][2] - The Xi'an Branch was also fined 5,000 RMB due to mismanagement leading to the loss of its license and failure to reapply or return the license as mandated [1][2]

1月7日，广受关注的《直播电商监督管理办法》(以下简称《办法》)由国家市场监管总局和国家网信办 联合发布，并将于2月1日正式实施。《办法》聚焦直播电商平台经营者、直播间运营者、直播营销人 员、直播营销人员服务机构四类主体，明确划定了行为红线，直播间运营者、直播营销人员不得进行虚 假宣传、不得进行商业诋毁、不得销售或者提供违法商品或者服务等。 在1月7日中国医药新闻信息协会举办的"大健康产品数字营销领航营"中，作为全程参与《办法》起草的 专家之一，国家市场监管总局新零售与直播电商专家委员会专家杜东为对《办法》的几大要点进行了解 析。 明确直播间运营者的身份公示、更新要求。《办法》规定，直播间运营者应当核验直播营销人员的姓 名、身份证件号码、经常居住地址、联系方式、所属直播营销人员服务机构以及与直播营销相关的专业 资质、职业职务等身份信息，并及时核验更新，保存相关记录备查，确保直播营销人员身份信息真实有 效。保存记录自直播结束之日起不少于三年。直播间运营者应当在每次直播前将核验无误的直播营销人 员身份信息报送直播电商平台经营者。直播电商平台经营者要求申请进入平台的直播间运营者提供上述 信息，同时，要求直播间运营者 ...

中国经济网北京1月8日讯 北京智谱华章科技股份有限公司（以下简称"智谱"，02513.HK）今日在港交所上市，开盘报 120.00港元，盘中最低价报116.10港元，跌破发行价。截至今日收盘，智谱报131.50港元，涨幅13.17%。 智谱是人工智能公司，致力于开发通用大模型。 根据发售价及配发结果公告，智谱本次发行超额配股权获行使前的发售股份数目为37,419,500股股份，其中，公开发售的最 终发售股份数目（于重新分配后）为7,483,900股股份，国际发售的最终发售股份数目（于重新分配后）为29,935,600股股 份。智谱于上市后已发行的股份数目为440,230,190股股份。智谱超额分配的发售股份数目为5,612,900股股份。 | 發售股份及股本 | | | --- | --- | | 超 額 配 股 權 獲 行 使 前 的 發 售 股 份 數 目 | 37.419.500 | | 公開發售的最終發售股份數目(於重新分配後) | 7.483.900 | | 國際發售的最終發售股份數目(於重新分配後) | 29,935,600 | | 於上市後已發行的股份數目 | 440,230,190 | | 超 ...

Core Viewpoint - The announcement from Morningstar Aviation regarding the shareholding changes of its controlling shareholder, Huiju Technology, indicates a planned reduction in shareholding that has now been partially executed, affecting the overall ownership structure of the company [1][2]. Group 1: Shareholding Changes - Morningstar Aviation's controlling shareholder, Huiju Technology, held 2,184,917,715 shares, representing 39.72% of the total share capital, and plans to reduce its holdings by up to 1% through centralized bidding and 2% through block trading within three months from the announcement date [1]. - As of January 6, 2026, Huiju Technology has reduced its holdings by a total of 1.0662% through the sale of 1,070,200 shares via centralized bidding and 4,795,000 shares via block trading, bringing its total shareholding down to 48.93% [1]. Group 2: Financial Impact - The weighted average price of Morningstar Aviation shares on January 6, 2026, was 16.964 yuan per share, resulting in a total reduction amount of approximately 99.4973 million yuan from the share sales [2]. - The actual number of shares reduced has not exceeded the planned reduction amount, indicating that the share reduction plan is still ongoing [2].

Core Viewpoint - TianShu ZhiXin Semiconductor Co., Ltd. (天数智芯) successfully listed on the Hong Kong Stock Exchange, opening at HKD 190.2 and closing at HKD 156.8, marking an increase of 8.44% from the opening price [1] Group 1: IPO Details - The total number of shares offered by TianShu ZhiXin was 25,431,800, with 2,543,200 shares allocated for public offering in Hong Kong and 22,888,600 shares for international offering [2] - The offering price was set at HKD 144.60, raising a total of HKD 3,677.4 million, with net proceeds amounting to HKD 3,509.3 million after deducting estimated listing expenses of HKD 168.2 million [3][4] Group 2: Use of Proceeds - The funds raised will be utilized for product and solution development, sales and marketing expansion, improving service quality, enhancing brand awareness, and general corporate purposes [5] Group 3: Financial Performance - TianShu ZhiXin reported revenues of RMB 189.4 million, RMB 289.0 million, RMB 539.5 million, RMB 197.4 million, and RMB 324.3 million for the years 2022, 2023, 2024, and the six months ending June 30, 2024, and 2025 respectively [6][7] - The company recorded net losses of RMB 553.6 million, RMB 817.4 million, RMB 892.4 million, RMB 404.0 million, and RMB 609.3 million for the same periods, totaling a cumulative loss of RMB 2.873 billion over three and a half years [6][7] Group 4: Cash Flow - Cash used in operating activities was RMB 653.8 million, RMB 707.0 million, RMB 618.0 million, and RMB 715.6 million for the years 2022, 2023, 2024, and the six months ending June 30, 2024, and 2025 respectively [8]

Core Viewpoint - The company Biyimi (必易微) is planning a share transfer of 698,379 shares, representing 1.00% of its total share capital, due to the shareholder's personal funding needs [1][2]. Group 1: Share Transfer Details - The shareholder involved in the transfer is Yuan Chengjun, who holds 17.58% of the company's shares [2]. - The share transfer will not occur through centralized bidding or block trading, and it is not classified as a secondary market reduction [2]. - The transfer price will be determined based on a minimum price that is no less than 70% of the average trading price over the 20 trading days prior to January 7, 2026 [2]. Group 2: Company Background and Financials - Biyimi was listed on the Shanghai Stock Exchange on May 26, 2022, with an issuance of 17,262,300 shares at a price of 55.15 yuan per share [3]. - The total funds raised from the initial public offering (IPO) amounted to 952.0158 million yuan, with a net amount of 860.7779 million yuan after deducting issuance costs [3]. - The company initially planned to raise 652.515 million yuan for various projects, including the development of power management control chips and motor drive control chips [3].

中国经济网北京1月8日讯 据同花顺数据显示，在刚过去的2025年12月份，易方达全球医药行业混合(QDII)C/A(人民币份额)单月下跌10.12%、10.11%。 截至2025年三季度末规模为20.67亿元。 | 代码 名称 | 区间复权单 累计单位净基金规模[3基金成立日基金经理(基金投资类投 | | --- | --- | | 019035.0F 易方达全球医药行业混合(QDII)C(人民币份额) | -10.12 1.22 7.49 2023-11-1 杨桢霄 混合型 QI | | 008284.0F 易方达全球医药行业混合(QDII)A(人民币份额) | -10.11 1.23 13.18 2020-01-2 杨桢霄 | (责任编辑：何潇) 2025年三季度前十大重仓股为前十大重仓股分别为复宏汉霖、信达生物、科伦博泰生、映恩生物、乐普生物、康诺亚、中国生物制药、翰森制药、三生 制、荣昌生物。该基金目前由基金经理杨桢霄管理，杨桢霄现任易方达基金管理有限公司基金经理。曾任易方达基金管理有限公司投资经理、行业研究员、 基金经理助理。 ...

Group 1 - The ice and snow tourism market shows significant growth potential, with 74.8% of respondents expressing interest in experiencing ice and snow leisure activities by the winter of 2025-2026 [3][5] - There is a shift in tourist spending from "hard" expenses like transportation and accommodation to "soft" expenses such as entertainment, wellness, cultural creativity, and technological experiences [3] - The ice and snow tourism landscape is evolving into a new pattern characterized by "north-south resonance, central rise, and east-west collaboration" [3] Group 2 - In 2025, the South China region is expected to lead in ice and snow tourism investment, accounting for 30% of total investments, approximately 30 billion yuan, with indoor ice and snow theme complexes being the most active investment category [4] - The ice and snow economy in China is projected to exceed 1 trillion yuan by 2025, with over 14,000 related enterprises, reflecting a year-on-year growth rate of 11% [6] - Among the newly established enterprises in 2025, 56.1% will focus on ice and snow tourism marketing, services, and event operations, while 18.1% will be related to training and education, including clubs and winter camps [6]

景顺长城景骊成长混合A成立于2021年05月07日，截至2026年01月07日，其今年来收益率为5.90%，成 立来收益率为-11.43%，累计净值为0.8856。景顺长城景骊成长混合C成立于2025年4月18日，成立来收 益率为16.70%。 | 基金名称 | 景顺长城景骊成长混合型证券投资基金 | | --- | --- | | 基金简称 | 景顺长城景骊成长混合 | | 基金主代码 | 010706 | | 基金管理人名称 | 景顺长城基金管理有限公司 | | 公告依据 | 《公开募集证券投资基金信息披露管理办法》 | | 基金经理变更类型 | 增聘基金经理 | | 新任基金经理姓名 | 郭琳 | | 共同管理本基金的其他经 | 梁荣 | | 理姓名 | | 中国经济网北京1月8日讯昨日，景顺长城基金公告，景顺长城景骊成长混合增聘郭琳。 郭琳曾任大成国际资产管理有限公司投资研究部高级研究员。2016年8月加入景顺长城，历任研究部研 究员、专户投资部投资经理、研究部基金经理助理，自2022年7月起担任股票投资部基金经理，现任研 究部基金经理。 ...

Core Viewpoint - Shenzhen Precision Medical Technology Co., Ltd. (referred to as "Precision Medical") was listed on the Hong Kong Stock Exchange, closing at HKD 56.6, a rise of 30.90% from its initial offering price of HKD 43.24 [1][4]. Group 1: IPO Details - The total number of shares offered globally was 27,722,200 H-shares, with 2,772,300 shares available for public offering in Hong Kong and 24,949,900 shares for international offering [2]. - The total amount raised from the offering was HKD 1,198.7 million, with net proceeds of HKD 1,116.6 million after deducting estimated listing expenses of HKD 82.1 million [4][6]. Group 2: Use of Proceeds - Approximately 23.0% of the net proceeds will fund research and development for the multi-port surgical robot, 19.0% for the single-port surgical robot, and 20.0% for the commercialization of core products [6]. - Additional allocations include 10.0% for capacity expansion, 8.0% for other products and ongoing research, 10.0% for potential strategic acquisitions or investments in the surgical robot industry, and 10.0% for working capital and general corporate purposes [6]. Group 3: Financial Performance - Precision Medical's revenues for 2023, 2024, and the first half of 2025 were HKD 48.0 million, HKD 160.0 million, and HKD 149.4 million, respectively, with losses of HKD 212.9 million, HKD 218.5 million, and HKD 89.1 million during the same periods [9][10]. - Cumulative losses for the years 2023 to the first half of 2025 totaled HKD 520 million [9]. Group 4: Key Investors - Major cornerstone investors include ADIA, UBS AM Singapore, OrbiMed Genesis, Tencent's Huang River Investment Limited, and several other investment funds [7][8].